Haviland Kate — SEC Form 4 filings
SEC reporting owner CIK 1663022. 15 Form 4 filings on record with FilingPulse; latest filed 2026-07-02.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-03-06 to 2026-07-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 5 filings — 34,912 shares, $3,167,741 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 16,151 shares @ $88.80 ($1,434,209) in Blueprint Medicines Corp, filed 2025-03-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) | Chief Executive Officer, Director | 8 | — | 10 legs · 34,912 sh · $3,167,741 | 17 |
| Bicara Therapeutics Inc. (BCAX) | Director | 3 | — | — | 3 |
| Fulcrum Therapeutics, Inc. (FULC) | Director | 3 | — | — | 3 |
| Avalyn Pharma Inc. (AVLN) | Director | 1 | — | — | 1 |
Form 4 filings — Haviland Kate
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Avalyn Pharma Inc. (AVLN) | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 129,210 · Disposition to issuer (D): 224,410 · Code (U): 70,729 · Disposition to issuer (D): 2 (derivative) · Disposition to issuer (D): 591 (derivative) · Disposition to issuer (D): 39,000 (derivative) · +7 more | EDGAR |
| 2025-06-30 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) | Grant/award (A): 23,746 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 600 @ $85.47 · Sale (S): 598 @ $86.14 · Sale (S): 1,200 @ $87.34 · Sale (S): 100 @ $88.59 | EDGAR |
| 2025-03-07 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 16,151 @ $88.80 | EDGAR |
| 2025-03-04 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 35,200 @ $0 · Grant/award (A): 70,400 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 1,446 @ $110.24 | EDGAR |
| 2024-12-03 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 400 @ $95.40 · Sale (S): 1,746 @ $96.74 · Sale (S): 207 @ $97.76 | EDGAR |
| 2024-09-16 | 4 | Bicara Therapeutics Inc. (BCAX) | Grant/award (A): 23,746 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 12,464 @ $90.69 | EDGAR |
| 2024-03-06 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1663022 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →